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Wnt1 Is Anti-Lymphangiogenic in a Melanoma
Mouse Model
Heide Niederleithner1,8, Magdalena Heinz1,8, Stefanie Tauber1,2, Martin Bilban3, Hubert Pehamberger4,
Stefan Sonderegger5, Martin Kno¨fler6, Andreas Bracher1, Walter Berger7, Robert Loewe1,4 and
Peter Petzelbauer1,4
Wnt signals contribute to melanoma progression by boosting their proliferation and survival. Initially, we
expected that activated Wnt signaling also improves their proficiency to recruit blood and lymph vessels. To
assess this, we added cell culture supernatants (SNs) of Wnt1þ and Wnt1 melanoma to endothelial spheroids.
Whereas SNs of Wnt1 melanoma cells induced lymphatic sprouts, those of Wnt1þ cells were unable to do so
and this was restored by vascular endothelial growth factor C (VEGF-C). Subsequent testing of several human
melanoma lines revealed that Wnt1 suppressed their VEGF-C expression. This Wnt1 effect did not depend on
glycogen synthase kinase-3b (GSK3b), b-catenin, or activator protein-1, but was blocked by cyclosporine A (CsA).
To analyze Wnt1 effects in melanoma in vivo, we selected Wnt1 melanoma cell lines, overexpressed Wnt1, and
injected them subepidermally into severe combined immunodeficient (SCID) mice. We found reduced VEGF-C
expression, reduced lymphangiogenesis, and delayed metastasis to sentinel nodes in Wnt1þ as compared with
Wnt1 melanoma (Po0.05). Concomitant overexpression of VEGF-C or feeding of animals with CsA restored
lymphangiogenesis and metastasis in Wnt1þ melanoma. In conclusion, Wnt1 is anti-lymphangiogenic by
suppressing melanoma-derived VEGF-C expression.
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INTRODUCTION
Wnt proteins comprise a family of 19 secreted glycoproteins
that activate the canonical pathway, resulting in the forma-
tion of a transcription factor complex containing b-catenin
and proteins of the T-cell factor (Tcf)/lymphocyte enhancer–-
binding factor (Lef) family (Fuerer et al., 2008). They
also signal through noncanonical pathways that activate
the calcineurin/NFAT (nuclear factor of activated T cells)
pathway and/or transcription factors of the activator protein-
1/Jun family (Staal et al., 2008). Wnt proteins are not
intrinsically canonical or noncanonical. Pathway decisions
are determined by distinct sets of receptors and coreceptors
(Mikels and Nusse, 2006; Spinsanti et al., 2008).
The association of Wnt pathways with malignancies was
first identified in familial adenomatous polyposis (Gardner,
1962), where a mutated APC (adenomatous polyposis coli)
gene leads to nuclear localization of b-catenin and to a
high risk for colon cancer (Groden et al., 1991). Nuclear
localization of b-catenin was subsequently used as a surrogate
marker for active Wnt signaling and mostly correlated with
poor outcome (Khramtsov et al., 2010). In melanoma, results
are contradictive: in human studies, loss of b-catenin was
found to be associated with disease progression (Kageshita
et al., 2001), high nuclear b-catenin was associated with
improved survival (Bachmann et al., 2005; Chien et al., 2009),
and high nuclear phospho-b-catenin was associated with
decreased survival (Kielhorn et al., 2003). In animal studies,
overexpression of b-catenin (Widlund et al., 2002; Sinnberg
et al., 2011) or the use of degradation-resistant b-catenin
(Damsky et al., 2011) increased melanoma proliferation and
metastasis, and silencing retarded growth but unexpectedly
promoted metastasis (Takahashi et al., 2008). In contrast,
overexpression of Wnt3a, which activates b-catenin, reduced
metastasis (Chien et al., 2009). Currently, the differences are
difficult to reconcile, in part, because nuclear b-catenin
cannot be equated with its translational activity and depends
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on cofactors (Eichhoff et al., 2011). Moreover, Wnt target
genes may affect outcomes by changing the secretome of
tumor cells that target blood or lymph vessels. In contrast to
‘‘canonical’’ Wnt proteins, expression of ‘‘noncanonical’’
WNT5a clearly correlates with melanoma progression (Da
Forno et al., 2008).
Canonical Wnt targets encompass a variety of angiogenic
regulators (e.g., Ephrins, FGF-2, FGF-18, FGF-20, endothelin-
1, Cx43, uPar, MMP7, and MMP3) (Brabletz et al., 1999;
Shimokawa et al., 2003; Hiendlmeyer et al., 2004; Kim et al.,
2005). Moreover, Wnt1 itself has been shown to induce
angiogenesis in vitro (Wright et al., 1999; Goodwin et al.,
2007; Zerlin et al., 2008), and genetic mutations of Wnt/
Frizzled genes result in abnormal vessel development
(Monkley et al., 1996; Ishikawa et al., 2001; Shu et al.,
2002). With regard to lymphangiogenesis, Wnt1 down-
regulates the lymphangiogenic factor vascular endothelial
growth factor D (VEGF-D) in a b-catenin-dependent manner
(Orlandini et al., 2003), but no data are available regarding
Wnt1 and lymphangiogenesis in vivo.
Lymphatic vessels are an important metastatic route
(Dadras et al., 2003, 2005; He et al., 2004). Particularly in
melanoma, there is a positive correlation between VEGF-C
expression, lymphangiogenesis, and metastasis (Skobe et al.,
2001; Goydos and Gorski, 2003; Schietroma et al., 2003;
Hoshida et al., 2006; Boone et al., 2008), but factors that alter
the ability of melanoma to induce lymphangiogenesis are yet
at the beginning of decipherment (Rinderknecht and Detmar,
2008). In this study, we analyzed the effect of activated Wnt
signaling on the proficiency of melanoma cells to recruit
blood and lymph vessels. We demonstrate that Wnt1 protects
the host from melanoma progression by suppressing the
release of melanoma cell–derived VEGF-C followed by
reduced lymphangiogenesis and metastasis.
RESULTS
Wnt1 suppresses melanoma-derived VEGF-C expression
To determine whether melanoma cells with an activated
Wnt1 signaling pathway release a profile of angiogenic
factors distinct from those being Wnt1 negative, we selected
Wnt1-negative melanoma cell lines A375 and M24met and
stably overexpressed Wnt1 (for Wnt1 protein and mRNA
expression, see Figure 1a; for expression of other Wnt
proteins, see Supplementary Figure S1 online). Supernatants
(SNs) of control melanoma cells added to lymph-endothelial
spheroids significantly induced sprouting compared with
spheroids stimulated with medium alone. Surprisingly, SNs
from Wnt1-overexpressing A375 were unable to induce
lymphatic endothelial cell sprouting (Figure 1b), but had no
effect on blood vessel spheroids (Supplementary Figure S2
online). As positive control, we used SNs from VEGF-C-
overexpressing A375 cells (for VEGF-C protein and mRNA
expression, see Figure 1a). A mixture of SNs of Wnt1-positive
and Wnt1-negative A375 cells, as well as a mixture of SNs of
Wnt1-positive and VEGF-C-overexpressing cells, restored
sprouting (Figure 1b). Melanoma cells are known to express
high levels of VEGF-C (Salven et al., 1998). When melanoma
cell lines (A375, M24met, VM54, and VM7) were stable or
transiently transfected with Wnt1 or treated with SNs from
Wnt1-overexpressing cells or treated with recombinant
Wnt3a, then VEGF-C expression was significantly decreased
as compared with control cells (Figure 1c).
Wnt1-induced VEGF-C suppression is independent from
b-catenin or glycogen synthase kinase-3b (GSK-3b) signaling
To characterize the pathway by which Wnt1 reduced VEGF-C,
we selected A375 cells for further experiments. We excluded a
b-catenin-dependent effect, because the concomitant over-
expression of DNTcf-4 (dominant negative Tcf-4 lacking b-
catenin-binding site) or of dickkopf-1 (DKK-1), both inhibitors
of the canonical Wnt pathway, did not antagonize the Wnt1-
induced reduction of VEGF-C (Figure 2a and b). AXIN2, a b-
catenin target, tested as positive control, was induced by Wnt1
and inhibited by DNTcf-4 or DKK-1 (Figure 2a). As controls, b-
catenin-dependent reporter constructs were tested in Wnt1-
overexpressing cells (Supplementary Figure S3 online).
WNT5a, tested for comparison as an established melanoma
progression protein, did not affect VEGF-C levels (Figure 2b).
In addition, inhibition of GSK-3b by LiCl and SB-415286 did
not affect VEGF-C expression (Figure 2c).
Wnt1-induced VEGF-C suppression is blocked by
cyclosporine A (CsA)
We next tested the effects of Wnt1 on noncanonical Wnt
pathways; Wnt1 induced NFAT-dependent transcription, but
had no effect on activator protein-1 and NF-kB reporters
(Supplementary Figure S3 online). To test for calcineurin,
which is upstream of NFAT, we stimulated cells with
ionomycin (activates the Ca2þ /Calmodulin dependent ki-
nase) and found a dose-dependent reduction of VEGF-C
mRNA expression (Figure 2d). To confirm a role of
calcineurin, the calcineurin inhibitor CsA was added to
Wnt1-overexpressing melanoma cells, which restored the
VEGF-C expression (Figure 2e). It is noteworthy that CsA did
not affect b-catenin-dependent transcription (Supplementary
Figure S3 online). To analyze whether Wnt1 suppressed
VEGF-C in a calcineurin/NFAT-dependent manner, we used a
dominant-negative NFAT construct (dnNFAT), which did not
alter VEGF-C expression, indicating that Wnt1 did not exert
its effects on VEGF-C via NFAT (Figure 2f). The functionality
of dnNFAT was confirmed by using a NFAT luciferase
reporter (Figure 2f). This suggests that Wnt1 triggers the
reduction of VEGF-C expression via activation of calcineurin
but not via NFAT transcription. The link between calcineurin
and VEGF-C expression yet remains open; at this point, we
have excluded altered VEGF-C mRNA stability being the
basis of the Wnt1 effect (Supplementary Figure S4 online).
Wnt1 overexpression delays melanoma metastasis
To investigate the effects of Wnt1 overexpression in vivo, we
injected Wnt1 and Wnt1þ melanoma cell lines into severe
combined immunodeficient (SCID) mice. Following orthoto-
pic grafting into the mouse dermis, Wnt1þ tumors expressed
Wnt1 protein (Figure 3a). Tumors were excised at a mean
tumor volume of 400mm3 (Figure 3c). The differences in
time until excision were not significant. Moreover, there
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were no differences in the numbers of Ki67-positive cells
(Supplementary Figure S5 online) or in in vitro proliferation
rates (Figure 3b). Animals were then monitored for sentinel
lymph node metastasis. In control vector–expressing A375
melanoma, macro-metastasis occurred after 18 days, whereas
in Wnt1-overexpressing A375 melanoma, the sentinel lymph
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Figure 1. Wnt1 suppresses melanoma-derived vascular endothelial growth factor C (VEGF-C) expression. (a) Wnt1 or VEGF-C protein and mRNA expression
from cell extracts or supernatants of A375 cells overexpressing Wnt1, VEGF-C, or control (Co) vector. (b) Lymphatic endothelial spheroids incubated with
supernatants (SNs) from A375 melanoma overexpressing a control vector, Wnt1, VEGF-C, or indicated combinations, or with recombinant (Rec.) Wnt3a
(100 ngml1) or medium alone for 6 hours. Numbers of sprouts were counted (mean±SD of three independent experiments). *Po0.05. (c) Melanoma lines
transiently or stably transfected with Wnt1 or stimulated with SNs of Wnt1-expressing A375 cells or with recombinant Wnt3a (100 ngml1). VEGF-C mRNA was
determined by real-time PCR. FCS, fetal calf serum.
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Figure 2. Wnt1 reduces vascular endothelial growth factor C (VEGF-C) expression independent of b-catenin and glycogen synthase kinase-3b (GSK3b).
(a, b) VEGF-C mRNA expression in A375 cells (a) stably or (b) transiently overexpressing control (Co; pLNCX) or indicated plasmids. The inserted western blot
shows VEGF-C protein expression from supernatants of control and Wnt1þ A375 cells. (c) A375 cells treated with GSK3b inhibitors for 16 hours. (d) A375 cells
stimulated with ionomycin or transiently transfected with Wnt1 or WNT5a plus ionomycin (8mM, 16 hours). (e) A375 cells stably overexpressing Wnt1 treated
with cyclosporine A (CsA). (f) A375 cells transiently expressing control vector, Wnt1, or WNT5a and co-transfected with empty vector or dominant-negative
nuclear factor of activated T cells (dnNFAT). The right graph confirms functionality of dnNFAT: cells transfected with control vector or dnNFAT plus luciferase
reporter controlled by NFAT-responsive elements were stimulated with DMSO, ionomycin (4 mM), or ionomycin/phorbol 12-myristate 13-acetate (PMA;
100 ngml1) for 16 hours. Mean±SD of three independent experiments, *Po0.05. DKK-1, dickkopf 1; Tcf, T-cell factor; DNTcf-4, dominant-negative Tcf-4
lacking b-catenin-binding site.
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nodes were free of tumor cells over an observation period of
60 days (Po0.001 compared with controls, Figure 3d,
n¼23, pooled results of 5 independent experiments). In
addition, histological serial sections of liver, lung, and brain
did not reveal any metastasis. Testing for VEGF-C mRNA
expression revealed significantly lower mRNA levels in A375
Wnt1þ melanoma as compared with control tumors (Figure
3e). VEGF-A mRNA expression tested for control purposes
did not show differences between groups (Figure 3e). On the
basis of in vitro effects of CsA on VEGF-C expression, animals
were fed with CsA. Whereas CsA had no effect on growth of
the primary tumors (Figure 3c), it reduced VEGF-C expression
(Figure 3e). Importantly, in the presence of CsA, Wnt1þ
melanomas were now able to metastasize to sentinel nodes
(Figure 3d). Finally, concomitant overexpression of VEGF-C
in Wnt1þ tumors also led to enhanced metastasis (Figure 3d).
To validate VEGF-C as the main lymphangiogenic factor
responsible for Wnt1 effects, expression profiling of lym-
phangiogenic factors was determined by Affymetrix micro-
arrays from M24met and A375 tumors, treated with or
without CsA (50mg kg1 per day). Data mining revealed
VEGF-C as the single best factor predicting early or delayed
metastasis (Figure 3f, raw data of the human Affymetrix gene
arrays are available by Gene Expression Omnibus (GEO)
repository). Genes shown in this figure had a cutoff of 410;
genes with a cutoff o10 were designated as being not
expressed and are not shown in this diagram (HGF, FGFR2,
IGF2, NRP2, ANGPT2, FLT1, PDGFRA, PDGFB, FLT4,
CALCR, CALCRL, IGF1, FGFR3, VEGF-D, and RAMP2).
Wnt1 overexpression reduces lymphangiogenesis in vivo
Histological evaluations of melanomas revealed numerous
dilated lymphatic vessels stuffed with tumor cells in control
tumors, whereas in Wnt1-positive tumors lymphatic vessels
were small-bored and mostly devoid of luminal mela-
noma cells (Figure 4a, lymphatics exemplified by arrows).
This was confirmed by double immunofluorescence with
anti-human vimentin (to identify human melanoma cells) and
Lyve-1 (to identify lymph vessels) (Figure 4a, right images).
Lymph vessel densities quantified by immunohistochemistry
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Figure 3. Wnt1 overexpression delays melanoma metastasis in severe combined immunodeficient (SCID) mice. (a) Immunohistochemistry with indicated
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PCR from A375-melanoma expressing control or Wnt1 vectors treated with or without cyclosporine A (CsA). Mean±SD, *Po0.05; n¼ 5 per group. (f) Heat map
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revealed a significant reduction of Lyve-1-positive vessels in
Wnt1-expressing tumors. Wnt1 expression had no effect on
blood vessel densities (Figure 4a). Results were confirmed by
real-time PCR; Lyve-1 and Prox-1 mRNA levels were sig-
nificantly reduced in Wnt1þ M24met (Figure 4b) as well as in
Wnt1þ A375 tumors (Figure 4c) when compared with controls.
CsA treatment and concomitant VEGF-C overexpression
resulted in increased lymphangiogenesis as evidenced by
increased Lyve-1 and Prox-1 mRNA levels (Figure 4c).
DISCUSSION
We show that Wnt1 significantly reduced melanoma-derived
VEGF-C expression and reduced lymphangiogenesis and
metastasis. This effect of Wnt1 was surprising, because so
far most downstream targets of Wnt signaling encompass
factors that induce the release of pro-angiogenic factors
(Brabletz et al., 1999; Shimokawa et al., 2003; Hiendlmeyer
et al., 2004; Kim et al., 2005), with the exception of a report
by Orlandini et al. (2003 demonstrating a b-catenin-
dependent decrease of VEGF-D mRNA expression mainly
due to reduced VEGF-D mRNA stability. VEGF-D is a known
lymphangiogenic factor, but in our melanomas VEGF-D was
not expressed. Instead, decreased VEGF-C expression was the
single best biomarker for effects of Wnt1 on reduced
lymphangiogenesis and metastasis, which is corroborated
by literature substantiating VEGF-C as a potent regulator of
lymphangiogenesis (Rinderknecht and Detmar, 2008; Lohela
et al., 2009). In our experiments, the addition of Wnt1-
containing media or recombinant Wnt3a to melanoma cells
reduced VEGF-C expression. Moreover, the anti-lymphangio-
genic effect of Wnt1 by melanoma cells in vitro and in vivo
was restored by the addition of VEGF-C.
To define pathways activated byWnt1 in melanoma, we used
reporter assays and found Wnt1 to induce b-catenin/Tcf- and
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NFAT-dependent transcription. A role for b-catenin was
excluded, because inhibition of b-catenin signaling by DKK-1
or a DNTcf-4 overexpression did not affect VEGF-C mRNA. A
role for calcineurin was suggested by the use of ionomycin,
which also reduced VEGF-C expression. To strengthen a role
for calcineurin, we added CsA to Wnt1þ cells and found
upregulation of VEGF-C expression in Wnt1þ A375 cells
in vitro. In vivo, feeding animals with CsA restored the ability
of Wnt1þ melanoma to induce lymphangiogenesis and to
metastasize.
The potential role of calcineurin in reducing VEGF-C
expression by Wnt1 raises the question of why WNT5a, also
an activator of calcineurin, was unable to reduce VEGF-C.
Our experiments did not clarify this, but we excluded the
assumption that Wnt1 effects on VEGF-C were based on an
additional GSK3b signal. GSK3b also activates NFAT and NF-
kB (Beurel and Jope, 2009) and is strongly targeted by Wnt1
and weakly by WNT5a, but neither inhibitors of GSK3b nor
dnNFAT altered VEGF-C expression. It is noteworthy that in
cell culture CsA restored high VEGF-C levels in melanoma
with a delay of 48 hours. Moreover, stable Wnt1 over-
expression was more efficient in downregulating VEGF-C
than transient Wnt1 overexpression (50% vs. 90% inhibition).
Cells apparently require an extended exposure to Wnt1 in
order to respond by reduced VEGF-C expression. This is in
line with our data that Wnt1 did not reduce VEGF-C via
NFAT at the level of the VEGF-C promoter. It suggests a not
yet defined indirect effect on VEGF-C transcription. However,
an indication for a protective role of calcineurin in cancer is
considered in a report showing that ‘‘hyperactivated’’
calcineurin inhibited the formation of an effective tumor
vasculature, which was restored by CsA (Ryeom et al., 2008),
but lymphangiogenesis was not evaluated. Thus, one could
speculate that Wnt1 mimics ‘‘hyperactivated’’ calcineurin.
In our experiments, Wnt1 had no effect on blood vessels,
which contrasts in vitro data: Wnt1 and Wnt3a induced
proliferation and migration of the endothelium through Wnt/
b-catenin signaling (Masckauchan et al., 2005; Samarzija
et al., 2009). In our in vivo experiments, VEGF-A expression
was equally high in all tumors; therefore, we speculate that
VEGF-A overwhelmed effects of Wnt1 on blood angiogen-
esis. However, with regard to cell culture experiments, we
show that recombinant Wnt3a increased lymph endothelial
sprouting in vitro, which is previously unreported to our
knowledge (Po0.05, Figure 1b; in our hands, recombinant
Wnt1 was nonfunctional). In other words, when Wnt proteins
directly target the endothelium, they induce angiogenesis.
When they target melanoma cells, they change their release
of lymphangiogenic factors and prevent lymphangiogenesis.
Our concept that canonical Wnt proteins may be
beneficial in melanoma is supported by a recent finding that
Wnt3a reduces melanoma metastasis (Chien et al., 2009),
which was correlated with increased b-catenin signaling.
However, this study did not investigate the effects on
lymphangiogenesis. Moreover, inhibitors for canonical or
noncanonical Wnt pathways were not used; thus, these
experiments did not rule out a role for calcineurin in
mediating the beneficial effects of Wnt3a in melanoma.
In conclusion, Wnt1 reduced melanoma-derived VEGF-C
in vitro. Moreover, Wnt1 reduced VEGF-C, lymphangiogen-
esis, and metastasis in vivo, but had negligible effects on cell
proliferation in vitro or on primary tumor growth in vivo. Our
data may open a door to consider Wnt1 as an anti-
lymphangiogenic treatment in melanoma (e.g., combined
with anti-VEGF-A treatment).
MATERIALS AND METHODS
Cell lines
The human melanoma cell line M24met (Mueller et al., 1991) was
cultured in RPMI (Invitrogen, Paisley, UK), and A375 cells (ATCC,
Wesel, Germany) in DMEM (Invitrogen) supplemented with 10%
fetal calf serum, 2mM L-glutamine, and 50Uml1 streptomycin/
penicillin (Invitrogen). VM54 and VM7 melanoma lines were
isolated from human primary melanoma (Metzner et al., 2011) and
cultivated in RPMI.
Antibodies and reagents
The following antibodies were used: goat anti-mouse Wnt1 and goat
anti-human VEGF-C antibodies (R&D, Minneapolis, MN), rabbit
anti-mouse Lyve-1 (Acris, Herford, Germany), rat anti-mouse CD34
(BD Pharmingen, San Diego, CA), mouse anti-human Vimentin
(clone V9, Dako, Glostrup, Denmark), biotinylated secondary
antibodies (Vector Laboratories, Burlingame, CA), horseradish
peroxidase rabbit anti-goat IgG (Zymax, San Francisco, CA), TRITC
goat anti-rabbit IgG (Jackson Laboratories, Bar Harbor, ME), and
Alexa 488 goat anti-mouse IgG (Molecular Probes, Eugene, OR). The
reagents used in the experiment were CsA, phorbol 12-myristate 13-
acetate, and ionomycin (Sigma-Aldrich, St Louis, MO), SB-415286
(GSK-3b inhibitor; Eubio, Vienna, Austria), LiCl (Serva Electrophor-
esis, Heidelberg, Germany), tumor necrosis factor-a (Pepro Tech,
Rocky Hill, NJ), and recombinant mouse Wnt3a (R&D).
Retroviral transduction
Phoenix cells (gift from H Stockinger, Medical University of Vienna,
Vienna, Austria) were transfected with retroviral pLNCX and Wnt1/
pLNCX DNA (gift from A McMahan, Harvard University, Cambridge
MA) by calcium phosphate precipitation to generate the retrovirus.
M24met melanoma cells stably infected with pLNCX or Wnt1 were
treated with 600mgml1 and A375 cells with 1,300mgml1
Geneticin (G-418, Biochrom AG, Berlin, Germany). Thereafter, cells
overexpressing Wnt1 or the empty pLNCX vector were double
infected with a second empty vector (pBMN-I-GFP), VEGF-C (cloned
into pBMN-I-GFP, gift from M Detmar, Institute of Pharmaceutical
Sciences, Zurich, Switzerland), and DNTcf-4 (cloned into pBMN-I-
GFP, gift of RG Pestell, Thomas Jefferson University, Philadelphia,
PA), or DKK-1-pBMN-I-GFP (gift from VJ Hearing, National Cancer
Institute, Bethesda, MD), and sorted for GFP-positive cells by FACS.
Transient transfection and luciferase reporter assays
OptiMeM (1ml, GIBCO, Paisley, UK) mixed with 4mg plasmid DNA
and 6ml Lipofectamine 2000 (Invitrogen) was added to cells at 80%
confluence. After 6 hours, the transfection mix was replaced by fresh
medium and cells were used 72hours later. The WNT5a/pcDNA3
plasmid was a gift from G Raguenez (Institut Gustave Roussy,
Villejuif, France).
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For luciferase assays, A375 cells were transfected with 500ng
NFAT reporter construct (pUBTluc-NFAT, gift of R de Martin, Medical
University Vienna), 500ng plasmid DNA (empty vectors or dominant-
negative NFAT; 1–130, gift of RJ Davis, University of Massachusetts
Medical School, Worchester, MA), and 1ng SV40 Renilla (Promega,
Madison, WI). After 30hours, DMSO, ionomycin, or phorbol 12-
myristate 13-acetate was added for 16hours. Cells were then lysed in
100ml passive lysis buffer using the Dual Luciferase Assay system kit
(Promega). Luciferase activity was measured with Berthold Centro LB
960 luminometer (Berthold Technologies, Bad Wildbad, Germany)
and monitored with the MikroWin 2000 software (Mikrotek
Laborsysteme, Overath, Germany). Data were reported as normalized
averages of the luciferase/Renilla ratio.
SCID mouse model
Animal procedures were approved by the animal care and use
committee (Medical University of Vienna). The xenograft model was
described previously (Loewe et al., 2006). Briefly, M24met (106) or
A375 (2 106) cells were injected subepidermally into the right
flank of 6-week-old female CB17 SCID mice (Charles River
Laboratories, Walmigton, MA). Tumor sizes were measured by a
caliper and calculated by the equation V¼ (p/6) (length) (width)2.
Tumors were excised after reaching a volume of 400mm3 and
defects were sutured. Excised tumors were divided into three parts
and transferred into RNAlater (Ambion, Paisley, UK), or fixed in 4%
formaldehyde or embedded in optimal cutting temperature com-
pound (Sakura, Zoetwoude, The Netherlands). Subsequently, animals
were monitored daily for palpable metastases in sentinel nodes (right
axilla). Mice with metastasis were killed and lymph nodes and lungs
harvested and processed as described for the primary tumors. Where
indicated, animals were fed with CsA (Kwizda, Vienna, Austria) via a
gauge starting at tumor grafting.
Immunohistochemistry
Sections (5mm) of paraffin-embedded tumors were stained with
hematoxylin and eosin, or deparaffinized and incubated in citrate
buffer (Dako). Sections were incubated with primary antibodies,
followed by appropriate biotinylated secondary antibodies and
visualized using horseradish peroxidase-conjugated Streptavidin kit
(Novocastra, Newcastle Upon Tyne, UK). For quantification of
CD34þ and Lyve-1þ vessels, five random fields (0.02mm2) were
photographed using an AxioCam MRc5 digital camera (Zeiss,
Oberkochen, Germany) attached to an AH3-RFCA microscope
(Olympus, Tokyo, Japan) and the Axio Vision Rel 4.4 Software
(Zeiss) and quantified by the semiautomatic program Image Scope
(Aperio Technologies, Vista, CA). For immunofluorescence double
staining, deparaffinized sections were incubated with anti-Lyve-1
and anti-Vimentin antibodies, followed by TRITC anti-rabbit and
Alexa 488 anti-mouse secondary antibodies. Nuclei were stained
using 40,6-diamidino-2-phenylindole, and sections were analyzed
on Zeiss confocal laser scanning microscope 510.
Real-time PCR
Cultured cells, SCID mouse–derived tumors, or 3mm biopsies from
human melanoma samples (approved protocol of the Vienna Ethics
committee) were homogenized in RLT lysis buffer, and total RNA
was extracted (RNeasy Mini Kit; Qiagen, Hilden, Germany) and
reverse transcribed with random hexamer primers (Revert Aid H
First-Strand cDNA synthesis kit; Fermentas, Glen Burnie, MD). Real-
time PCR primers (FAM Primers) were from Applied Biosystems
(Carlsbad, CA), Assays-on-demand. Reaction mixtures contained 1ml
complementary DNA, 12.5 ml TaqMan Universal PCR Master Mix
(Applied Biosystems), and 1.25 ml Assay-on-demand in a total
volume of 25 ml. Cycling parameters were as follows: 50 1C for
2minutes, then 95 1C for 10minutes, followed by 40 cycles of 95 1C
for 10 seconds and 60 1C for 1minute. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) for human primers and b-2 microglobulin
for mouse primers were used as housekeeping genes. Reactions were
run on StepOnePlus Real-Time PCR; data analysis was performed
with the StepOnePlus Software v2.0 (Applied Biosystems). mRNA
concentrations were determined by subtracting CT of the house-
keeping gene from CT of the target gene (D¼CT geneCT GAPDH).
The mean of D control was subtracted from the D target gene
reaction (DDCT¼D target genemean D control). The difference
was calculated as 2(DDCT).
Gene expression microarray
For Affymetrix chips, 5mg of total RNA was reverse transcribed into
second-strand complementary DNA (Affymetrix, Santa Clara, CA)
according to the manufacturer’s instructions. Preparation of cRNA,
hybridization to Human Genome U133 Plus 2.0, and scanning were
carried out according to the manufacturer’s protocols (www.
affymetrix.com). RNA signal extraction and normalization was
performed as described (www.bioconductor.org). To calculate dif-
ferential expression between the individual sample groups, statistical
comparisons were performed using the limma package implemented
in the Bioconductor suite (www.bionconductor.org), which esti-
mates the fold change between predefined sample groups by fitting a
linear model and using an empirical Bayes method to moderate
the standard errors of the estimated log-fold change for each
probe set. An absolute log-fold change cutoff of 1 was chosen
and a multiple-testing correction based on the false discovery rate
was performed to produce adjusted P-values (www.jstor.org/pss/
2346101). All microarrays have been deposited in the GEO
repository (http://www.ncbi.nlm.nih.gov/geo/) under accession num-
ber GSE26656.
Western blot
For analysis of SNs, A375 cells were seeded in serum-free medium
for 24 hours. SNs were harvested and precipitated with 100%
ethanol, and incubated at 20 1C overnight. Precipitates were
harvested by centrifugation at 4 1C. After washing in cold 70%
ethanol, pellets were dissolved in sample buffer (7.5 M urea; 1.5 M
thiourea; 4% CHAPS; 0.05% SDS). For cell extracts, A375 cells were
lysed in RIPA buffer and 30 mg protein lysates were loaded onto SDS
gels, electrophoresed, and blotted. Membranes were blocked in 1%
I-block (TROPIX, Bedford, MA), followed by incubation with
primary and secondary antibodies, and bound antibodies were
visualized by chemiluminescence (ECL plus, Amersham, UK) and by
exposure to Hyperfilm ECL.
Proliferation assay
A375 cells were seeded in 96-well plates (2,000 cells per well). After
24 or 48hours, cell numbers were determined by EZ4U cell
proliferation and cytotoxicity assay (Biomedica, Vienna, Austria)
by ELISA at 450 nm.
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Spheroid sprouting assay
Lymphatic endothelial cells were isolated from human foreskin and
separated by magnetic sorting with an anti-podoplanin serum
(Gro¨ger et al., 2007). To extend their lifespan, they were lentivirally
infected with the human telomerase gene (hTERT). Spheroids were
produced as described (Korff and Augustin, 1999), embedded into
collagen gels, and incubated with serum-free SNs from indicated
cells (collected after 48 hours) supplemented with 0.5% fetal calf
serum. As a negative control, lymphatic endothelial cells were
incubated in fresh medium supplemented with 0.5% fetal calf
serum. Pictures were taken after 6 hours and numbers of sprouts
were counted blinded to conditions.
Statistical analysis
All experiments were conducted in triplicates and repeated at least
twice. Data are expressed as mean±SD, and significance was
assessed by Student’s t-test. In case of more than two groups, analysis
of variance followed by Tukey’s Honestly Significant Difference
was calculated. For Figure 3d, the w2 test for homogeneity was used,
followed by paired comparison under control of the false discovery
rate.
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